🔴 Cerenome is trading 5.66% down today amid broader market weakness after the Fed rate hike

Cerenome is trading 5.66% down now at $2.00 after broad market weakness following the Federal Reserve’s 25-basis-point rate hike and hawkish outlook.

• The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are all lower, increasing pressure on smaller growth companies.
• Cerenome announced Samantha Fowlkes as head of commercial sales for CNSide Diagnostics on September 16, 2026, but the release does not link the appointment to the share-price decline.